Researchers conduct a spatio-temporal analysis of mesothelioma incidence. They also examine asbestos exposure patterns. The study relies on statistical modeling of incidence rates. Cancer registry records and occupational history data provide the main sources. Scientists map cases across different regions and time periods. They identify clusters and changing trends. In addition, they link these patterns […]
Tag: Anticancer Drugs
KRAS-Targeted Drugs: From Molecular Discovery to Clinical Application Introduction KRAS is one of the most important oncogenic drivers in human cancer. It belongs to the RAS family of small GTPases. These proteins regulate cell growth, survival and proliferation. For decades, KRAS was considered difficult to target with drugs. Scientists struggled to find suitable binding sites […]
Analysis of Immune Checkpoint Inhibitor Efficacy in Mesothelioma Immune checkpoint inhibitors have changed treatment approaches for several cancers. Researchers now examine their effectiveness in mesothelioma. Studies stratify results by PD-L1 expression and histological subtype. This analysis helps identify which patients benefit most. PD-L1 expression serves as a key biomarker. Higher PD-L1 levels often correlate with […]
In this article we will discuss Cytoreductive Surgery and HIPEC in Peritoneal Malignancies
In this article we will discuss Oncogenic Signaling Pathways: PI3K/AKT/mTOR
CAR-T therapy has transformed treatment for certain blood cancers. However, solid tumours present greater challenges. The immunosuppressive microenvironment and limited T-cell trafficking reduce effectiveness. Researchers therefore develop multiple strategies to overcome these barriers. Solid tumours create a hostile local environment. Dense stroma, low oxygen levels, and inhibitory molecules restrict CAR-T cell function. Regulatory immune cells […]